Although no PI3K inhibitors are currently approved for AML treatment, several PI3K/AKT pathway inhibitors, including the PI3Kα-selective inhibitors alpelisib and inavolisib, are approved for other malignancies and have reasonable toxicity profiles in patients [55, 56]. This evidence concerns the gene AKT1 and acute myeloid leukemia.